LST scores and mutational signatures were inferred in the 16 PALB2-associated breast cancers analyzed by WES, of which 13 cases were found to display high LST scores (LSThigh), and nine cases (eight LSThigh and one LSTlow) were found to have a dominant mutational signature 3 associated with HRD (i.e., BRCA1/2 signature; Table 1, Figs. 1 and 3a). This evidence concerns the gene PALB2 and breast cancer.